| Bioactivity | Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins[1]. Hematin can be used for the research of acute porphyrias and cancer[1][2][3][4][5]. | ||||||||||||
| Invitro | Hematin (0.01 mg/ml) inhibits the clotting of bovine fibrinogen (1.3 to 2.6 mg/ml) by bovine thrombin (0.12 U/ml) and inhibits the hydrolysis of a synthetic substrate by human thrombin[2].Hematin (0.035 mg/ml) reduces VIII:C activity from 0.88 to 0.40 U/ml[2].Hematin (0.05 mg/ml) inhibits the activation of VIII:C by thrombin (0.04 U/ml)[2].Hematin (0.09 mg/ml) inhibits the hydrolysis of a synthetic substrate by plasmin[2]. | ||||||||||||
| In Vivo | Hematin (i.v.; single injection) suppressed porphyrin production in SD rat (weighing 160-205 g)[4]. | ||||||||||||
| Name | Hematin | ||||||||||||
| CAS | 15489-90-4 | ||||||||||||
| Formula | C34H33FeN4O5 | ||||||||||||
| Molar Mass | 633.49 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Siegert SW, et al. Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review. Adv Ther. 2008 Sep;25(9):842-57. [2]. Green D, et al. The inactivation of hemostatic factors by hematin. J Lab Clin Med. 1983;102: 361-369. [3]. Amin ML, et al. Development of hematin conjugated PLGA nanoparticle for selective cancer targeting. Eur J Pharm Sci. 2016 Aug 25;91:138-43. [4]. Goetsch C, et al. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986;315: 235-238. [5]. Quadros HC, et al. The Role of the Iron Protoporphyrins Heme and Hematin in the Antimalarial Activity of Endoperoxide Drugs. Pharmaceuticals (Basel). 2022;15(1):60. Published 2022 Jan 4. |